Aiosyn
Aiosyn sells AI that analyzes images of stained tissue, to pathology laboratories and to drug companies running animal studies. It is a spin out of Radboud University Medical Center in Nijmegen, the Netherlands.
For laboratories, AiosynQC checks scanned slides for problems like blur, folds and color errors before a pathologist reads them. Aiosyn Mitosis marks dividing cells in breast cancer slides, and NephroPath scores kidney biopsies, including the scores used in kidney transplant care. All three are sold for research use, and none is CE marked as a diagnostic in Europe. Laboratories reach them through image platforms such as Sectra's Amplifier marketplace, HistoWiz and Techcyte's Fusion.
For drug companies and contract research organizations, Aiosyn runs ready made analyses of animal tissue for atherosclerosis, brain, liver and kidney studies, with results in about a week. It also builds custom models on a client's own images.
Aiosyn's quality system is ISO 13485 certified. No price is published.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
The models are the product. Every Aiosyn offering is AI image analysis: slide quality control, mitosis detection, kidney biopsy outlining and scoring, ready made preclinical readouts, and custom models built on a client's images. Aiosyn sells no scanner, viewer or laboratory service that would stand without them.
Pathologist review is built into the laboratory products, but no threshold is published. Aiosyn Mitosis marks detected mitoses in the slide viewer before case review, so the pathologist confirms them. AiosynQC flags slides with focus, fold, scan or color problems for rescanning or review. NephroPath outlines and classifies structures in the viewer for the pathologist to assess. Preclinical readouts were validated against pathologist scoring.
What is missing is the operating point: the confidence at which a mitosis is marked, the quality score at which a slide is flagged, and what happens when a pathologist disagrees with the output.
Each product is described by what it detects, but nothing identifies the models. Aiosyn names the structures and measurements each product outputs, and builds on more than 20 years of computational pathology research at Radboudumc. Its news pages list earlier research by its founders on mitosis detection with convolutional networks trained against a PHH3 reference standard, without tying it to a product version.
No model architecture, training data, version or update practice is published for any product.
Aiosyn builds its own models, from Radboudumc research and its own development, and no outside model provider is named or implied. Cloudflare is named as a processor for the website under a data processing addendum.
The infrastructure and subprocessors that handle customer slide images are not described. Nor is the role of partner platforms such as Sectra and HistoWiz in processing them.
Named preclinical work comes with figures and method, and the laboratory products have studies without published figures. In a validation with TNO on 80 aortic root cases, Aiosyn reports that its AI lesion area readouts matched expert pathologist scoring with a Pearson correlation of 0.96. A diabetic kidney disease study with Physiogenex, published in the European Journal of Pharmaceutical Sciences (2026), used NephroPath to detect the effect of dapagliflozin in rats. Aiosyn's academic partners include Radboudumc, Amsterdam UMC and Leiden University Medical Center.
A clinical performance study of Aiosyn Mitosis with Radboudumc, involving 28 pathologists from nine countries, was presented at USCAP and ECDP in 2024 as improving efficiency and consistency, and the company's pages give no figures from it. ZAS Netwerk in Belgium began evaluating the mitosis product in clinical settings in 2024. No performance figures are published for AiosynQC, Aiosyn Mitosis or NephroPath on human slides, and no study shows an effect on diagnosis.
Privacy terms exist but are general, and they leave images and training use unaddressed. The privacy policy says data is kept no longer than necessary, and that product support exchanges may be kept for up to ten years for post market surveillance.
Nothing published says how long customer slide images are kept, whether they are used to train or improve models, or how training data from partner hospitals was deidentified. Custom models are built on a client's images, with no statement of who may reuse them. No safety engineering for the models is published.
The privacy policy reaches part of the service, and takes no position on patient data. The policy of Aiosyn B.V., effective 24 August 2026 and written under the GDPR, covers website visitors and its preclinical research services. It names Cloudflare as a processor under a data processing addendum, with standard contractual clauses for transfers outside the European Economic Area.
It does not address patient slide images processed for laboratory customers and says nothing about HIPAA. No data processing agreement for customer images is published.
Aiosyn publishes no independent security attestation. It holds ISO 13485 certification from BSI, which audits its quality system for medical device development, not how it runs information security. No ISO/IEC 27001 certificate, NEN 7510 certificate, SOC 2 report, penetration testing statement or trust center appears on its site.
Aiosyn makes no device claim and states each product's position, though one product is presented beyond its label. It states that AiosynQC is not a medical device under the EU IVDR or UK MDR 2002, and is for research use only in the United States. Aiosyn Mitosis is for research use only. NephroPath is for research use only, not CE marked and not for diagnostic procedures. Aiosyn holds ISO 13485 for its quality system, and the FDA's databases list no Aiosyn device.
Aiosyn Mitosis is presented on the clinical page to diagnostic laboratories as marking mitoses before routine case review. That sits uneasily with its research use label, since the mitotic count is part of breast cancer grading.
Experts take part in validation, but no results compared across groups are published. Aiosyn works with a scientific advisory board of three named nephrologists and pathologists for NephroPath, validates preclinical models against pathologist scoring, and runs a pathologist network.
No results are published by scanner, stain, laboratory, species or patient group. No governance framework or monitoring after release is described.
Pathologists can review each output, but nothing stands behind it. Detections and outlines are shown in the pathologist's viewer for review, and quality control flags slides rather than removing them, so a pathologist can challenge each output.
No error rate for the laboratory products, warranty, remedy or correction route is published, and the products are labeled for research use.
No clinical record integration exists. The products reach laboratories through named image platforms instead. NephroPath is listed on Sectra's Amplifier marketplace and connected to HistoWiz's PathologyMap. Aiosyn announced with Techcyte that slide quality control and mitotic counting integrate into Techcyte's Fusion platform, and in March 2025 Techcyte, Pramana and Aiosyn announced mitosis and kidney analysis running inline with Pramana scanners, with results shown in the Fusion viewer as DICOM annotations. Aiosyn also names Pathomation and Argos among its integration partners. Results appear in the pathologist's existing viewer, flowing one way from the AI into the image platform.
The analysis is delivered as a service, and where it runs is implied, not stated. Aiosyn analyzes preclinical images and returns the results, and the laboratory products run through partner viewers and platforms. The company is Dutch, and its privacy policy names standard contractual clauses for processing outside the European Economic Area.
There is no statement of where customer images are processed or stored, which cloud is used beyond Cloudflare for the website, or whether the products can run on premises.
No price is published, but how each route is sold can be worked out. Drug company and contract research customers buy analyses from existing models, with readouts in about a week, or custom model development on their own images. Laboratory products reach customers inside viewers and platforms, including Sectra's Amplifier marketplace, HistoWiz's PathologyMap and Techcyte's Fusion.
No rate per slide, per study or per license is published.
Coverage is named product by product, with validation behind part of it. Preclinical analyses cover atherosclerosis, brain, liver and kidney tissue, with a TNO atherosclerosis validation and a published rat kidney study. Laboratory products cover quality control of H&E and immunohistochemistry slides, mitosis detection in breast cancer, and kidney biopsy assessment including the Banff ci and ct scores. Those are for kidney pathology laboratories and transplant centers, under research use.
Aiosyn also sells preclinical readouts and custom models to drug companies and contract research organizations. No validation on human slides is published for the laboratory products.
Alternatives to Aiosyn
Other products that do the same kind of work as Aiosyn, and what each one does.
AIRA Matrix, from AIRA Matrix Private Limited of Thane, India, sells deep learning image analysis for pathology to drug developers and laboratories.
Tribun Health sells CaloPix, software that pathology laboratories use to manage cases and review scanned slides on screen.
PictorLabs, which now styles its name Pictor Labs, makes software that stains tissue images with AI instead of chemicals, and a tissue intelligence platform built on it.
Aperio iQC DX is Leica Biosystems' AI quality check for digital pathology slides. Clinical laboratories that scan slides on Leica's Aperio GT scanners use it to catch bad scans before a pathologist sees them.
Histotype Px Colorectal predicts recurrence and survival in stage II and III colorectal cancer from standard H and E stained slides, placing patients in low, intermediate or high risk groups to inform whether adjuvant chemotherapy should follow surgery.
Techcyte sells Fusion, a digital pathology platform that human, veterinary and environmental laboratories use for both anatomic and clinical pathology.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Preclinical analysis by study with readouts in about a week, custom model development, and laboratory products licensed through image platforms such as Sectra Amplifier and HistoWiz PathologyMap. No rate published. | Not published. The privacy policy is written under the GDPR and covers the website and preclinical services; no data processing or business associate agreement for customer images is published. | Not published. | Vendor Published |
Aiosyn describes how biopharma customers buy analyses and custom models, and that laboratory products are reached through partner viewers and marketplaces, without a price, unit of charge or license term. No price per study or per slide and no marketplace license terms are published.